Combination therapy with DMARDs and biological agents in collagen-induced arthritis.
There is increasing interest in the use of combination therapy for rheumatoid arthritis and in the possibility of combining the conventional drug approach with newer biological therapies. Animal models of arthritis provide important tools for evaluating novel forms of therapy and for eludicating mechanisms of drug action. In this paper, we review the results of our own research into combination therapy in collagen-induced arthritis using biological therapies such as anti-tumor necrosis factor alpha, anti-CD4, and anti-interleukin 12 monoclonal antibodies, and small molecular weight compounds such as cyclosporin and the phosphodiesterase IV (PDE IV) inhibitor rolipram.
Williams
R O
RO
Kennedy Institute of Rheumatology, London, UK.
Malfait
A M
AM
Butler
D M
DM
Walmsley
M J
MJ
Feldmann
M
M
Maini
R N
RN
D000818:Animals; D018501:Antirheumatic Agents / Q000276:immunology* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology*; D003094:Collagen / Q000009:adverse effects*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D007167:Immunotherapy; D051379:Mice
D018501:Antirheumatic Agents; D003094:Collagen